Dr. Tanya B. Dorff

Dr. Tanya B. Dorff, MD, is a nationally recognized medical oncologist specializing in genitourinary cancers, with particular expertise in prostate, bladder, and testicular malignancies. She currently serves as the Chair of the Department of Medical Oncology and Therapeutics Research at City of Hope National Medical Center in Duarte, California, one of the nation’s leading cancer research and treatment institutions. Dr. Dorff earned her medical degree from the University of California, Los Angeles (UCLA), and completed her internal medicine residency at Cedars-Sinai Medical Center, followed by a fellowship in hematology/oncology at the University of California, Irvine. She is board-certified in both Internal Medicine and Medical Oncology and is widely regarded for her patient-centered approach to complex cancer care.

Dr. Dorff is a leading voice in the field of prostate cancer research, having led and contributed to numerous clinical trials investigating cutting-edge therapies, including immunotherapy, CAR-T cell therapy, androgen-targeting agents, and PARP inhibitors. Her work has been instrumental in developing new strategies for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequencing and combination therapies that have influenced national guidelines. She has authored and co-authored over 100 peer-reviewed publications and frequently lectures at national and international oncology symposia. Her clinical interests also include supportive care and quality-of-life outcomes for patients undergoing advanced cancer treatment.

In addition to her clinical and research roles, Dr. Dorff is a respected educator and mentor. She actively trains residents, fellows, and junior faculty, and fosters multidisciplinary collaboration across urology, radiation oncology, and molecular diagnostics. She is a contributing member of the National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines Panel and serves as a co-chair of the SWOG Genitourinary Committee, where she helps shape clinical trial design and therapeutic standards. Dr. Dorff is also affiliated with several key professional organizations, including the American Society of Clinical Oncology (ASCO), the American Urological Association (AUA), and the American Association for Cancer Research (AACR). With a career devoted to scientific innovation, personalized medicine, and compassionate patient care, Dr. Tanya Dorff continues to lead transformative advancements in the field of genitourinary oncology.